Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group, Inc.

Replimune Group, Inc. (NASDAQ: REPL) and several current or former company leaders have asked a federal court in Massachusetts to dismiss an invest...

Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process

Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that investors were not told key facts about regulatory weakne...

Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop

Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that the company misled investors about the regulatory strengt...

Replimune Group Lawsuit Alleges Investors Were Misled Before REPL Stock Drop

Past performance may not guarantee future results, but it can still provide valuable clues. When a stock suddenly breaks higher on unusually strong...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REPL	$15.50	-0.64%	2.39M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REPL	$15.50	-0.6%	2.39M
3
4
5
6

REPL

Get Replimune Group, Inc. Data in Excel

Get Replimune Group, Inc. Data in Excel